Plant-Based Vaccines, Antibodies & Biologics

8-10 June 2015, University of LausanneCHUV, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size


Commercial protein drugs, which include recombinant monoclonal antibodies, subunit vaccines, immune modulators, and human enzymes, will exceed $200 billion within 2-3 years. A component of this extraordinary growth is the availability of new technologies to speed the time to market of new biologics, and to create improved versions of existing drugs. Among the new developments is the emerging use of green plants for recombinant protein production due to advantages over yeast, cultured mammalian or insect cells, or other living systems. It is becoming increasingly evident that:

  • Government regulatory agencies have accepted plant production in new drug approval and licensure
  • Monoclonal antibody production in plants offers rapid production advantages in comparison to mammalian cells, with at least equivalent product safety, purity and potency
  • Metabolic engineering of tobacco as a host for protein production is advancing rapidly to allow highly uniform drug products, including post-translational modifications similar to those of human cells
  • Plant-based manufacturing platforms hold major promise for next generation biogenerics (or biobetters with improved pharmacokinetic properties)
  • Plant-made subunit vaccines are in the pipeline for multiple infectious diseases
  • Ongoing corporate drug development at commercial scale is providing data to accurately determine the potential to reduce manufacturing cost of protein drugs under cGMP requirements using plant protein expression as the starting point

PBVAB 2015 is the sixth meeting in this important and successful series. PBVAB 2015 will offer an international forum to review the current state of research in plant protein expression systems, down-stream processing technology, the pipeline of products now in development (including vaccines, monoclonal antibodies, and human enzymes), and efforts in using these technologies in areas beyond human health (including disease prevention in animals and aquaculture).

PBVAB 2015 will aim to attract an international audience of researchers, clinicians, and representatives for academia, industry and government/regulatory/public health organizations. Representatives for the human, veterinary, plant communities with an interest in vaccinology, immunology, biotechnology issues in relation to plant-based systems will find PBVAB 2015 of value. PBVAB 2015 will seek to develop the synergy between the human and veterinary medical/immunological/plant biotechnology communities by focusing on the immunology, vaccinology, delivery, adjuvants, and efficacy of plant based proteins.

PBVAB 2015 will aim to emphasise the take-off of the commercialisation of plant-based biologic products, the requirement for more academic based research to respond to the  question: Where is the pipeline of products going to come from and what have we learned on the decision-making processes for that product pipeline?

Scientific Advisory Panel

Conference Chairman: Julian Ma (St. George’s University of London, London, UK)

Diego Orzaez (CSIC, University of Valencia, Spain)
George Lomonossoff (John Innes Centre, Norwich, UK)
Kevin Whaley (Mapp Biopharmaceutical Inc., USA)
Rainer Fischer (RWTH Aachen, Germany)
Charles Arntzen (Arizona State University, Tempe, Arizona, USA)
Pascal Drake (St. George’s University of London, London, UK)
Ed Rybicki (University of Capetown, South Africa)
Yuri Gleba (Icon Genetics GmbH, Halle, Germany)
Hugh Haydon (Kentucky BioProcessing, Owensboro, Kentucky, USA)
Scott Deeter (Ventria Bioscience, Fort Collins, Colorado, USA)
Marc-Andre D’Aoust (Medicago Inc., Quebec, Canada)
Ann Depicker (University of Ghent, Ghent, Belgium)
Yoseph Shaaltiel (Protalix Biotherapeutics, Carmiel, Israel)
Takeshi Matsumura (AIST, Japan)
Marcos da Silva Freire (Bio-Manguinhos/Fiocruz, Brazil)
Andres Wigdorovitz (INTA, Buenos Aires, Argentina)
Sun Lee (NEXGEN Biotechnologies Inc., Seoul, South Korea)
Robert Erwin (iBio Inc., Newark, Delaware, USA)

Conference Sessions/Topics

Main Sessions:

  • Challenges to Commercialisation
  • Product Pipelines
  • Vaccines
  • Antibodies
  • Adjuvants
  • Biologics
  • Expression Systems
  • Pre-clinical & Clinical Evaluations
  • Regulatory & Socio-ethical Issues

The PBVAB 2015 conference will focus on the following main topics:

  • Global need for vaccines and antibodies that can address large, cost-sensitive markets
  • Plant-based protein expression systems
  • Molecular pharming issues
  • Plant viral vector expression systems
  • Plant-derived antigens & adjuvants
  • Production and scale-up
  • Plant-derived antibodies with infectious agent targets/new targets
  • Purification and GHP manufacture
  • Regulatory control
  • Biofuels
  • Containment strategies (physical/genetic)
  • Delivery systems
  • Biofortification
  • Preventing pathogen transmission across mucosal surfaces
  • Downstream processing issues
  • Clinical trials
  • Biosafety/regulatory/public health issues

Whilst this list is not exhaustive it does give an indication of the main focus of PBVAB 2015 and the areas where abstract submissions for both oral and poster presentation are being encouraged by the Scientific Advisory Panel.

Announcing the launch of the

International Society for Molecular Farming

Preliminary details are available at:

Please contact: Professor Julian K-C. Ma, Hotung Chair of Molecular Immunology, Joint Director, Institute for Infection and Immunity, St. George’s Hospital Medical School, University of London,
Cranmer Terrace, London SW17 0RE, United Kingdom

Tel: 020 8725 5818  Fax: 020 8725 3487  E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it


PBVAB 2015 Delegates

Login details will be supplied after you have registered for the event.

PBVAB 2015 Sponsors

  • Epso
  • Aldevron
  • Medicago
  • Protalix Biotherapeutics
  • Retroscreen Virology
  • Fraunhofer IME
  • Intrucept Biomedicine
  • Synthon
  • Nomad
  • Nexgen
  • Icon Genetics
  • Conviron
  • The International Society For Plant Molecular Farming
  • Ilvo
  • Molecular Farming
  • PBL
  • Plant Transformation Technologies
  • Mapp BioPharmaceutical
  • Kentucky Bioprocessing
  • Angany Genetics
  • Planet Biotechnology
  • PlantForm
  • iBioPharma
  • Root Lines Technology
  • BioVaxx
  • Ventria Bioscience
  • John Innes Centre
  • Fraunhofer USA
  • Greenovation

PBVAB 2015 Downloads

PBVAB 2015 Leaflet

PBVAB 2015 Mailing List

E-mail Address
What is 3+2-1?